Krystal Biotech (KRYS) Competitors $167.61 +3.97 (+2.43%) (As of 12/16/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KRYS vs. BGNE, TEVA, MRNA, VTRS, GMAB, SMMT, SRPT, RDY, PCVX, and CTLTShould you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include BeiGene (BGNE), Teva Pharmaceutical Industries (TEVA), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Krystal Biotech vs. BeiGene Teva Pharmaceutical Industries Moderna Viatris Genmab A/S Summit Therapeutics Sarepta Therapeutics Dr. Reddy's Laboratories Vaxcyte Catalent BeiGene (NASDAQ:BGNE) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Do institutionals & insiders believe in BGNE or KRYS? 48.5% of BeiGene shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 7.4% of BeiGene shares are held by insiders. Comparatively, 14.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend BGNE or KRYS? BeiGene presently has a consensus price target of $253.69, indicating a potential upside of 43.87%. Krystal Biotech has a consensus price target of $206.67, indicating a potential upside of 23.30%. Given BeiGene's higher probable upside, research analysts clearly believe BeiGene is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeiGene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, BGNE or KRYS? BeiGene has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Does the media refer more to BGNE or KRYS? In the previous week, Krystal Biotech had 3 more articles in the media than BeiGene. MarketBeat recorded 16 mentions for Krystal Biotech and 13 mentions for BeiGene. BeiGene's average media sentiment score of 0.40 beat Krystal Biotech's score of 0.31 indicating that BeiGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeiGene 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor BGNE or KRYS? BeiGene received 259 more outperform votes than Krystal Biotech when rated by MarketBeat users. Likewise, 69.24% of users gave BeiGene an outperform vote while only 67.29% of users gave Krystal Biotech an outperform vote. CompanyUnderperformOutperformBeiGeneOutperform Votes54769.24% Underperform Votes24330.76% Krystal BiotechOutperform Votes28867.29% Underperform Votes14032.71% Which has better earnings and valuation, BGNE or KRYS? Krystal Biotech has lower revenue, but higher earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeiGene$3.32B5.18-$881.71M-$8.24-21.40Krystal Biotech$50.70M95.08$10.93M$1.7794.70 Is BGNE or KRYS more profitable? Krystal Biotech has a net margin of 21.68% compared to BeiGene's net margin of -25.94%. Krystal Biotech's return on equity of 7.54% beat BeiGene's return on equity.Company Net Margins Return on Equity Return on Assets BeiGene-25.94% -25.12% -14.95% Krystal Biotech 21.68%7.54%6.97% SummaryKrystal Biotech beats BeiGene on 13 of the 18 factors compared between the two stocks. Ad WealthPressIs the Trump/Musk duo good for shares of TSLA?If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRYS vs. The Competition Export to ExcelMetricKrystal BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.82B$2.97B$4.98B$9.32BDividend YieldN/A1.86%4.85%4.01%P/E Ratio94.7044.56103.2117.62Price / Sales95.08356.791,299.0482.42Price / CashN/A182.1341.3438.32Price / Book6.073.924.864.93Net Income$10.93M-$41.89M$117.35M$225.47M7 Day Performance-9.11%-5.43%14.41%-1.15%1 Month Performance-1.83%6.89%18.99%5.92%1 Year Performance44.79%22.00%38.20%22.97% Krystal Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRYSKrystal Biotech4.3152 of 5 stars$167.61+2.4%$206.67+23.3%+44.8%$4.71B$241.52M94.70229BGNEBeiGene2.629 of 5 stars$207.62+1.0%$253.69+22.2%-3.7%$20.23B$2.46B0.0010,600TEVATeva Pharmaceutical Industries3.1788 of 5 stars$17.69+2.1%$19.67+11.2%+65.3%$20.04B$15.85B0.0037,851MRNAModerna4.4147 of 5 stars$44.44+3.5%$83.33+87.5%-51.4%$17.10B$6.85B0.005,600VTRSViatris1.8058 of 5 stars$12.72-1.3%$13.67+7.4%+22.0%$15.18B$15.43B-17.1938,000GMABGenmab A/S4.2742 of 5 stars$22.19+1.7%$45.20+103.7%-35.1%$14.68B$2.39B21.172,204Short Interest ↓SMMTSummit Therapeutics3.4001 of 5 stars$18.70+0.9%$34.00+81.8%+629.7%$13.79B$700,000.000.00105SRPTSarepta Therapeutics4.9126 of 5 stars$129.57+1.1%$175.55+35.5%+36.3%$12.38B$1.24B102.541,314Insider TradePositive NewsRDYDr. Reddy's Laboratories1.8687 of 5 stars$14.55-0.1%$17.00+16.8%+10.3%$12.14B$3.35B23.2827,048PCVXVaxcyte1.8093 of 5 stars$91.83-1.6%$147.50+60.6%+47.8%$11.45BN/A0.00160Positive NewsCTLTCatalent2.7655 of 5 stars$62.12+0.5%$63.40+2.1%+53.0%$11.28B$4.38B0.0016,900 Related Companies and Tools Related Companies BGNE Alternatives TEVA Alternatives MRNA Alternatives VTRS Alternatives GMAB Alternatives SMMT Alternatives SRPT Alternatives RDY Alternatives PCVX Alternatives CTLT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRYS) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KRYS Stock Alerts